Regulation of hTERT by BCR-ABL at multiple levels in K562 cells

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Chai, Juin Hsien ^a   Zhang, Yong ^a   Tan, Wei Han ^a   Chng, Wee Joo ^a,b,c   Li, Baojie ^d   Wang, Xueying ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Dept Medicine Endocrinol Diabet   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; MESSENGER RNA; STAT5A PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; TELOMERASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HL 60; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA MODIFICATION; DOWN REGULATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LOCATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LEUKEMIA CELL; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; DRUG EFFECT; METABOLISM; METHODOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; DOWN-REGULATION; FUSION PROTEINS, BCR-ABL; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICROARRAY ANALYSIS; PIPERAZINES; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RNA, MESSENGER; TELOMERASE; TUMOR CELLS, CULTURED;

EID: 83055192083     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-512     Document Type: Article

References (59)

1. Nowell PC. Discovery of the Philadelphia chromosome: a personal perspective. J Clin Invest 2007, 117(8):2033-2035. 10.1172/JCI31771, 1934591, 17671636.
2. Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell 1986, 47(2):277-284. 10.1016/0092-8674(86)90450-2, 3021337.
3. Clark SS, McLaughlin J, Timmons M, Pendergast AM, Ben-Neriah Y, Dow LW, Crist W, Rovera G, Smith SD, Witte ON. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science 1988, 239(4841 Pt 1):775-777.
4. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243(5405):290-293. 10.1038/243290a0, 4126434.
5. Butturini A, Arlinghaus RB, Gale RP. BCR/ABL. Encyclopedia of Cancer 2002, 1:6.
6. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007, 7(6):441-453. 10.1038/nrc2147, 17522713.
7. Mandanas RA, Leibowitz DS, Gharehbaghi K, Tauchi T, Burgess GS, Miyazawa K, Jayaram HN, Boswell HS. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. Blood 1993, 82(6):1838-1847.
8. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3 k/Akt-dependent pathway. EMBO J 1997, 16(20):6151-6161. 10.1093/emboj/16.20.6151, 1326299, 9321394.
9. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci USA 1995, 92(25):11746-11750. 10.1073/pnas.92.25.11746, 40479, 8524841.
10. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 1992, 70(6):901-910. 10.1016/0092-8674(92)90241-4, 1525828.
11. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247(4946):1079-1082. 10.1126/science.2408149, 2408149.
12. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2(5):561-566. 10.1038/nm0596-561, 8616716.
13. John S. The molecular biology of cancer. Molecular Aspects of Medicine 2001, 21:57.
14. O'Dwyer ME, Gatter KM, Loriaux M, Druker BJ, Olson SB, Magenis RE, Lawce H, Mauro MJ, Maziarz RT, Braziel RM. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003, 17(3):481-487. 10.1038/sj.leu.2402848, 12646934.
15. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ, Reddel RR. Protein composition of catalytically active human telomerase from immortal cells. Science 2007, 315(5820):1850-1853. 10.1126/science.1138596, 17395830.
16. Shay JW, Keith WN. Targeting telomerase for cancer therapeutics. Br J Cancer 2008, 98(4):677-683. 10.1038/sj.bjc.6604209, 2259186, 18231105.
17. Bock O, Serinsoz E, Schlue J, Kreipe H. Different expression levels of the telomerase catalytic subunit hTERT in myeloproliferative and myelodysplastic diseases. Leuk Res 2004, 28(5):457-460. 10.1016/j.leukres.2003.09.006, 15068898.
18. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999, 400(6743):464-468. 10.1038/22780, 10440377.
19. Aisner DL, Wright WE, Shay JW. Telomerase regulation: not just flipping the switch. Curr Opin Genet Dev 2002, 12(1):80-85. 10.1016/S0959-437X(01)00268-4, 11790559.
20. Kang SS, Kwon T, Kwon DY, Do SI. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem 1999, 274(19):13085-13090. 10.1074/jbc.274.19.13085, 10224060.
21. Liu JP. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J 1999, 13(15):2091-2104.
22. Lankat-Buttgereit B, Horsch D, Barth P, Arnold R, Blocker S, Goke R. Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth. Digestion 2005, 71(3):131-140. 10.1159/000084647, 15785039.
23. Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J, Birenbaum M, Bakhanashvili M, Yerushalmi R, Luria D, et al. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer 2005, 92(10):1881-1891. 10.1038/sj.bjc.6602592, 2361771, 15870711.
24. Wihlidal P, Karlic H, Pfeilstocker M, Klaushofer K, Varga F. Imatinib mesylate (IM)-induced growth inhibition is associated with production of spliced osteocalcin-mRNA in cell lines. Leuk Res 2008, 32(3):437-443. 10.1016/j.leukres.2007.07.020, 17822760.
25. Mor-Tzuntz R, Uziel O, Shpilberg O, Lahav J, Raanani P, Bakhanashvili M, Rabizadeh E, Zimra Y, Lahav M, Granot G. Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL-positive) cells sensitive and resistant to imatinib. Exp Hematol 2010, 38(1):27-37. 10.1016/j.exphem.2009.10.005, 19837126.
26. Campbell LJ, Fidler C, Eagleton H, Peniket A, Kusec R, Gal S, Littlewood TJ, Wainscoat JS, Boultwood J. hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia 2006, 20(4):671-679. 10.1038/sj.leu.2404141, 16498395.
27. Phatak P, Burger AM. Telomerase and its potential for therapeutic intervention. Br J Pharmacol 2007, 152(7):1003-1011. 2095101, 17603541.
28. Baird DM, Rowson J, Wynford-Thomas D, Kipling D. Extensive allelic variation and ultrashort telomeres in senescent human cells. Nat Genet 2003, 33(2):203-207. 10.1038/ng1084, 12539050.
29. Opitz OG. Telomeres, telomerase and malignant transformation. Curr Mol Med 2005, 5(2):219-226. 10.2174/1566524053586626, 15974876.
30. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002, 1(7):493-502. 10.1038/nrd839, 12120256.
31. Hartmann U, Balabanov S, Ziegler P, Fellenberg J, van der Kuip H, Duyster J, Lipp HP, Bokemeyer C, Kanz L, Brummendorf TH. Telomere length and telomerase activity in the BCR-ABL-transformed murine pro-B cell line BaF3 is unaffected by treatment with imatinib. Experimental Hematology 2005, 33(5):542-549. 10.1016/j.exphem.2005.02.002, 15850831.
32. Yi X, Shay JW, Wright WE. Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res 2001, 29(23):4818-4825. 10.1093/nar/29.23.4818, 96692, 11726691.
33. Bellon M, Nicot C. Central role of PI3K in transcriptional activation of hTERT in HTLV-I-infected cells. Blood 2008, 112(7):2946-2955. 10.1182/blood-2008-01-134692, 2556626, 18511807.
34. Nakatake M, Kakiuchi Y, Sasaki N, Murakami-Murofushi K, Yamada O. STAT3 and PKC differentially regulate telomerase activity during megakaryocytic differentiation of K562 cells. Cell Cycle 2007, 6(12):1496-1501.
35. Horikawa I, Cable PL, Mazur SJ, Appella E, Afshari CA, Barrett JC. Downstream E-box-mediated regulation of the human telomerase reverse transcriptase (hTERT) gene transcription: evidence for an endogenous mechanism of transcriptional repression. Mol Biol Cell 2002, 13(8):2585-2597. 10.1091/mbc.E01-11-0107, 117927, 12181331.
36. Wellbrock C, Weisser C, Hassel JC, Fischer P, Becker J, Vetter CS, Behrmann I, Kortylewski M, Heinrich PC, Schartl M. STAT5 contributes to interferon resistance of melanoma cells. Curr Biol 2005, 15(18):1629-1639. 10.1016/j.cub.2005.08.036, 16169484.
37. Liu K, Hodes RJ, Weng N. Cutting edge: telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation. J Immunol 2001, 166(8):4826-4830.
38. Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL + leukemia cells. J Clin Invest 2008, 118(9):3038-3050. 10.1172/JCI33337, 2515380, 18704194.
39. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264(5164):1415-1421. 10.1126/science.8197455, 8197455.
40. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000, 19(21):2474-2488. 10.1038/sj.onc.1203527, 10851046.
41. Ye D, Wolff N, Li L, Zhang SM, Ilaria RL. STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood 2006, 107(12):4917-4925. 10.1182/blood-2005-10-4110, 1895818, 16522816.
42. Ilaria RL, Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996, 271(49):31704-31710. 10.1074/jbc.271.49.31704, 8940193.
43. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996, 13(2):247-254.
44. Decker T, Kovarik P. Transcription factor activity of STAT proteins: structural requirements and regulation by phosphorylation and interacting proteins. Cell Mol Life Sci 1999, 55(12):1535-1546. 10.1007/s000180050393, 10526571.
45. Hoelbl A, Schuster C, Kovacic B, Zhu BM, Wickre M, Hoelzl MA, Fajmann S, Grebien F, Warsch W, Stengl G, et al. Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Molecular Medicine 2010, 2(3):98-110. 10.1002/emmm.201000062, 2906698, 20201032.
46. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 2000, 95(6):2118-2125.
47. Lin JX, Leonard WJ. The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene 2000, 19(21):2566-2576. 10.1038/sj.onc.1203523, 10851055.
48. Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang DM, Brown M, Bodner S, Grosveld G, Ihle JN. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 1998, 93(5):841-850. 10.1016/S0092-8674(00)81444-0, 9630227.
49. Socolovsky M, Fallon AEJ, Wang S, Brugnara C, Lodish HF. Fetal anemia and apoptosis of red cell progenitors in Stat5a(-/-)5b(-/-) mice: A direct role for Stat5 in Bcl-X-L induction. Cell 1999, 98(2):181-191. 10.1016/S0092-8674(00)81013-2, 10428030.
50. Liu XW, Robinson GW, Wagner KU, Garrett L, WynshawBoris A, Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Gene Dev 1997, 11(2):179-186. 10.1101/gad.11.2.179, 9009201.
51. Park SH, Liu X, Hennighausen L, Davey HW, Waxman DJ. Distinctive roles of STAT5a and STAT5b in sexual dimorphism of hepatic P450 gene expression. Impact of STAT5a gene disruption. J Biol Chem 1999, 274(11):7421-7430. 10.1074/jbc.274.11.7421, 10066807.
52. Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, Terrell S, Klitgaard JL, Santo L, Addorio MR, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 2011, 117(12):3421-3429. 10.1182/blood-2009-11-255232, 21233313.
53. Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Holbl A, Gleixner KV, Dworzak M, Mayerhofer M, Hoermann G, et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 2011, 117(12):3409-3420. 10.1182/blood-2009-10-248211, 21220747.
54. Liu JP. Protein phosphorylation events in exocytosis and endocytosis. Clin Exp Pharmacol Physiol 1997, 24(8):611-618. 10.1111/j.1440-1681.1997.tb02101.x, 9269537.
55. Li H, Zhao LL, Funder JW, Liu JP. Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells. J Biol Chem 1997, 272(27):16729-16732. 10.1074/jbc.272.27.16729, 9201974.
56. Kharbanda S, Kumar V, Dhar S, Pandey P, Chen C, Majumder P, Yuan ZM, Whang Y, Strauss W, Pandita TK, et al. Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase. Curr Biol 2000, 10(10):568-575. 10.1016/S0960-9822(00)00483-8, 10837221.
57. Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006, 108(7):2332-2338. 10.1182/blood-2006-02-004580, 1895563, 16772610.
58. Scherr M, Chaturvedi A, Battmer K, Dallmann I, Schultheis B, Ganser A, Eder M. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood 2006, 107(8):3279-3287. 10.1182/blood-2005-08-3087, 16278304.
59. Donato NJ, Wu JY, Zhang L, Kantarjian H, Talpaz M. Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. Blood 2001, 97(9):2846-2853. 10.1182/blood.V97.9.2846, 11313280.